Wednesday, November 18, 2026 Vol. I · No. 6
Business · Via CNBC

CEO turned informant: How the FDA built a case against executives promising cheap medications

The FDA's unprecedented criminal case against an alternative funding program hinged on the cooperation of a peer CEO, according to a court record.

This is a brief. The reporting belongs to CNBC — read the complete story, with full context and credits, at the source.

Read the full story at CNBC ↗

cnbc.com

More from the Business desk